Evidence map›Paper›PMID 23360712›Full record

ArticleBMC research notes2013

Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples.

Douglas W Mahoney, Terry M Therneau, S Keith Anderson, Jin Jen, Jean-Pierre A Kocher, Monica M Reinholz, Edith A Perez, Jeanette E Eckel-Passow

Abstract read
In one paragraph

Article in BMC research notes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Trial
  2. Article
  3. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Douglas W MahoneyBiomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. mahoney@mayo.edu
Terry M Therneau
S Keith Anderson
Jin Jen
Jean-Pierre A Kocher
Monica M Reinholz
Edith A Perez
Jeanette E Eckel-Passow

Funding

TRANSLATIONAL RESEARCHU10CA025224 · NCI · MAYO CLINIC ROCHESTER · PI BUCKNER, JAN C · 1985 to 2013
$85.0M
North Central Cancer Treatment Group (NCCTG) Biospecimen ResourceU24CA114740 · NCI · MAYO CLINIC ROCHESTER · PI BUCKNER, JAN C · 2005 to 2014
$8.6M
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup TrialR01CA129949 · NCI · MAYO CLINIC JACKSONVILLE · PI PEREZ, EDITH A. · 2008 to 2011
$1.3M
NCI NIH HHS CA114740NCI NIH HHS CA129949NCI NIH HHS CA25224
6 · The paper itself

Abstract

backgroundFormalin fixed, paraffin embedded tissues are most commonly used for routine pathology analysis and for long term tissue preservation in the clinical setting. Many institutions have large archives of Formalin fixed, paraffin embedded tissues that provide a unique opportunity for understanding genomic signatures of disease. However, genome-wide expression profiling of Formalin fixed, paraffin embedded samples have been challenging due to RNA degradation. Because of the significant heterogeneity in tissue quality, normalization and analysis of these data presents particular challenges. The distribution of intensity values from archival tissues are inherently noisy and skewed due to differential sample degradation raising two primary concerns; whether a highly skewed array will unduly influence initial normalization of the data and whether outlier arrays can be reliably identified.

findingsTwo simple extensions of common regression diagnostic measures are introduced that measure the stress an array undergoes during normalization and how much a given array deviates from the remaining arrays post-normalization. These metrics are applied to a study involving 1618 formalin-fixed, paraffin-embedded HER2-positive breast cancer samples from the N9831 adjuvant trial processed with Illumina's cDNA-mediated Annealing Selection extension and Ligation assay.

conclusionProper assessment of array quality within a research study is crucial for controlling unwanted variability in the data. The metrics proposed in this paper have direct biological interpretations and can be used to identify arrays that should either be removed from analysis all together or down-weighted to reduce their influence in downstream analyses.

Indexed as

Gene Expression ProfilingAntibodies, Monoclonal, HumanizedBreast NeoplasmsClinical Trials, Phase III as TopicCyclophosphamideDNA, ComplementaryDoxorubicinErb-b2 Receptor Tyrosine KinasesFemaleGenome, HumanHumansModels, StatisticalOligonucleotide Array Sequence AnalysisPaclitaxelParaffin EmbeddingQuality ControlAntibodies, Monoclonal, HumanizedCyclophosphamideDNA, ComplementaryDoxorubicinErb-b2 Receptor Tyrosine KinasesPaclitaxelRNATrastuzumab

Identifiers

PMID23360712
PMCPMC3626608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.